NasVax Ltd. Announces the Success of a Phase 2a Clinical Trial of a New Oral Immunotherapy for Fatty Liver Disease
NESS ZIONNA, Israel--(BUSINESS WIRE)--NasVax (TASE: NSVX) (“Company”) announces the success of a Phase 2a clinical trial of a new oral immunotherapy for non-alcoholic steatohepatitis (NASH), an inflammatory disease associated with fatty liver disease and the metabolic syndrome.